Trial site
Texas Oncology-Dallas Presbyterian Hospital
Dallas, Texas 75231, United StatesNot linked to an institution yet
- 8running trials
- 3closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 22 trials
- Status
- Active, not recruiting8 trials
- Completed3 trials
- Lead sponsor
- Acrivon Therapeutics1 trial
- Eli Lilly and Company1 trial
- Hoffmann-La Roche1 trial
- Loxo Oncology, Inc.1 trial
- NSABP Foundation Inc1 trial
- and 6 more
Running trials
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395· Phase 3· Tolmar Inc.· Source
Active, not recruiting
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
MYLUNG Consortium Study Protocol 2
NCT05644808· US Oncology Research· Source
Active, not recruiting
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
NCT04625270· Phase 2· Verastem, Inc.· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Active, not recruiting
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954· Phase 3· NSABP Foundation Inc· Source
Report an error